Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

ABSTRACT: Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466.

SUBMITTER: Sharp A 

PROVIDER: S-EPMC5302169 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature